Supporting Information for

Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: α-synuclein phosphorylation at Tyrosine 125

Mirva Hejjaoui ^{#1}, Sara Butterfield ^{#1}, Bruno Fauvet ¹, Filip Vercruysse ¹, Jia Cui ², Igor Dikiy ³, Michel Prudent ¹, Diana Olschewski ¹, Yan Zhang ², David Eliezer ³ and Hilal A. Lashuel ^{1*}

These authors contributed equally to this work

¹ Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland

² Laboratory of Neurobiology and State Key Laboratory of Biomembrane and Membrane Biotechnology, College of Life Sciences, Peking University, Beijing, China

³ Department of Biochemistry and Program in Structural Biology, Weill Cornell Medical College, New York, New York 10021, USA

* Corresponding author: hilal.lashuel@epfl.ch

- I. Synthesis and characterization of α -syn C-terminal peptides
- II. Generation of α -syn (1-106)SR N¹⁵ labeled and non-labeled
- III. Semisynthesis and purification of WT α -syn T and pY125 α -syn
- IV. Generation of α -syn A107C ¹⁵N labeled and Semisynthesis of α -syn A107C_pY125 ¹⁵N labeled.
- V. TEM images of recombinant and semisynthetic α -syn after 7 days of aggregation
- VI. Analysis of HEK, HeLa cells and mouse neurons treated with pervanadate: detection of non-specific bands
- VII. Cross-talk between α -syn phosphorylation at S87 and Y125: *in vitro* phosphorylation assay
- VIII. Complete references 5, 20, 34, 44 and 49

I. Synthesis and characterization of α -syn C-terminal peptides

Peptide: α-Syn(A107C-140)

sequence: CPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA synthetic specifications: couplings used HBTU; double couplings performed at Cys107, Glu109, Met-116, Asp-119, and Met-127 yield: 25% expected mass: 3886 Da



Figure S1. a) MALDI-TOF analysis (observed mass=3885.85Da) and b) RP-HPLC analysis of purified α -syn A107C-140 on a C₁₈ analytical column (CosmoSil Protein-R, 4.6x250 mm, 5µm particle size) with a linear gradient of 0 to 80%B over 30min (A: water/0.1%TFA and B: acetonitrile/0.1% TFA).

Peptide: α-syn(A107C-140)_pY125 sequence: CPQEGILEDMPVDPDNEA-pY-EMPSEEGYQDYEPEA synthetic specifications: see above yield: 25%

expected mass: 3969 Da



Figure S2. a) MALDI-TOF analysis (observed mass= 3968 Da). b) RP-HPLC analysis of purified α -syn A107C-140_pY125 on a C₁₈ analytical column (CosmoSil Protein-R, 4.6x250 mm, 5µm particle size) with a linear gradient of 0 to 80%B over 30min (A: water/0.1%TFA and B: acetonitrile/0.1% TFA).

II. Generation of ¹⁵N-labeled α -syn(1-106)SR and non-labeled α -syn(1-106)SR



Figure S3. a) MALDI-TOF analysis (observed mass= 10739). The mass 5367 corresponds to the double-charged. b) RP-HPLC analysis of purified α -syn(1-106)SR on a C₄ analytical column (CosmoSil 5C₄) with a linear gradient of 0 to 80%B over 15min (A: water/0.1%TFA and B: acetonitrile/0.1% TFA).

¹⁵N labeled α -syn (1-106)SR



Figure S4. a) MALDI-TOF analysis (observed mass= 10870). The mass 5434 corresponds to the double-charged. b) RP-HPLC analysis of purified α -syn(1-106)SR ¹⁵N labeled on a C₄ analytical column with a linear gradient of 0 to 80%B over 30min (A: water/0.1%TFA and B: acetonitrile/0.1% TFA)

α-SynA107C wild-type



Figure S5. SDS-PAGE analysis of native chemical ligation reaction between α -syn(1-106)SR and α -syn(A107C-140).



Figure S6. a) MALDI-TOF analysis of the desulfurized product (expected mass: 14461). The mass of 14676 corresponds to a sinapinic matrix adduct and the mass of 7233 to the double-charged. b) RP-HPLC of semi-synthetic WT α -syn on an analytical C18 with a linear gradient of 0 to 80%B over 30min (A: water/0.1%TFA and B: acetonitrile/0.1% TFA).

α-synA107C_pY125



Figure S7. SDS-PAGE analysis of native chemical ligation reaction between α -syn(1-106)SR and α -syn(A107C-140_pY125). Note: the ligation corresponding to the gel was done with two molar excess of α -syn(1-106)SR.



Figure S8. a) MALDI-TOF analysis of the desulfurized product (expected mass: 14541). The mass of 14744 corresponds to a sinapinic matrix adduct and the mass of 7220 to the double-charged. b) RP-HPLC of semi-synthetic pY125 α -syn on an analytical C18 with a linear gradient of 0 to 80%B over 30min (A: water/0.1%TFA and B: acetonitrile/0.1% TFA).

General scheme of ligation and purification



Figure S9. Scheme of the main steps for the generation of pY125 α -syn: ligation, desulfurization and purification by chromatographic methods.



Figure S10. Scheme of the cation-exchange chromatography purification of pY125 α -syn.



Figure S11. A: SDS-PAGE analysis of the fractions containing pY125 α -syn (eluting from the cation exchange column at pH 5). B: SDS-PAGE analysis of the pure lyophilized pY125 α -syn.

<u>IV. Generation of α -syn A107C N¹⁵ labeled and Semisynthesis of α -syn A107C_pY125 N¹⁵ labeled.</u>

α -synA107C ¹⁵N labeled



Figure S12. a) MALDI-TOF analysis of the protein (expected mass: 14659). The mass of 14866 corresponds to a sinapinic matrix adduct and the mass of 7329 to the double-charged. b) RP-HPLC of ¹⁵N labeled α -syn A107C on an analytical Protein-R C₁₈ column with a linear gradient of 0 to 80%B over 30min (A: water/0.1%TFA and B: acetonitrile/0.1% TFA).

α-synA107C_pY125¹⁵N labeled



Figure S13. a) MALDI-TOF analysis of the ligated product (expected mass: 14701). The mass of 14913 corresponds to a sinapinic matrix adduct and the mass of 7350 to the double-charged. b) RP-HPLC of semi-synthetic pY125 α -syn ¹⁵N labeled on an analytical Protein-R C₁₈ column with a linear gradient of 0 to 80%B over 30min (A: water/0.1%TFA and B: acetonitrile/0.1% TFA).

V. TEM images of recombinant and semisynthetic WT α -syn



Figure S14. TEM images of recombinant WT and semisynthetic α -syn incubated for 7 days on a rotating wheel at 37°C. The images are representative of 3 independent experiments. The scale bars represent 200nm.



VI. Analysis of HEK and HeLa cells and mouse neurons treated with pervanadate: detection of non-specific bands

Figure S15. A. Immunoblots of HEK293 (left) and HeLa (right) cells over-expressing WT α -syn and treated with pervanadate for 5, 10 and 20min. Membranes were probed with WT α -syn (Biomol SA3400) and pY125 antibodies (BD Pharmigen). B. Immunoblots of mouse α -syn KO primary neurons treated with pervanadate for 30min. Membranes were probed with WT α -syn (BD transduction laboratory) and pY125 antibodies (BD Pharmigen).



Figure S16. Confocal images of HeLa cells over-expressing WT or Y125F α -syn and treated with pervanadate for 30min. The cells were fixed and stained with anti-pY125 antibody (BD pharmigen) and anti- α -syn (abcam).



<u>VII</u>. Cross-talk between α-syn phosphorylation at S87 and Y125: <u>in vitro</u> phosphorylation assay

Figure S17. **A**: Immunoblots of pY125 α -syn phosphorylated using CK1 and PLK3. Membranes were probed using pS87, pY125, and α -syn antibodies. **B**: Immunoblots of pS87 α -syn phosphorylated using Syk, Lyn, Fyn, c-Src, and c-Fgr. Membranes were probed for pY125, pS87, and α -syn immunoreactivity. **D**: MALDI-TOF analysis of pS87 α -syn (a) phosphorylated by Syk (b), Lyn (c), Fyn (d), c-Src (e), and c-Fgr (f) after 14h of reaction. In all MALDI-TOF-MS spectra, the symbol 'n' indicates the starting material peak, while the numbers above other peaks correspond to the number of phosphorylation events, each detected by a +80 Da mass shift. The symbol '*' indicates a sinapinic acid matrix adduct.

Supporting information for the figure S17:

To obtain site-specific phosphorylation at S87, S129A α -syn was incubated with CKI until phosphorylation at S87 was complete, then pS87 α -syn was purified by reversed-phase HPLC, and incubated with the tyrosine kinases in the same conditions as in the experiment with pS129 α -syn. Using first the mutant S129A α -syn, we showed that the S129A mutation itself did not influence phosphorylation at Y125 (not shown). Using the purified pS87 α -syn, we observed that the behavior of pS87 α -syn is similar to that of pS129 α -syn and WT α -syn: phosphorylation at Y125 by Syk is very efficient as judged by Western Blot (Supplementary Figure S17 B) but again not specific as shown by MALDI-TOF MS (Supplementary Figure S17 C (b)). We noted, however, that pS87 α -syn might be more efficiently phosphorylated at Y125 by Fyn than pS129 α -syn, since a single phosphorylation event could be seen with pS87 α -syn but not pS129 α -syn. However, Western-Blot data does not support a large effect.

VIII- Complete references 5, 21, 30, 40 and 45

(5) Polymeropoulos, M. H.; Lavedan, C.; Leroy, E.; Ide, S. E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; Stenroos, E. S.; Chandrasekharappa, S.; Athanassiadou, A.; Papapetropoulos, T.; Johnson, W. G.; Lazzarini, A. M.; Duvoisin, R. C.; Di Iorio, G.; Golbe, L. I.; Nussbaum, R. L. *Science* **1997**, *276*, 2045.

(20) Inglis, K. J.; Chereau, D.; Brigham, E. F.; Chiou, S. S.; Schobel, S.; Frigon, N. L.; Yu, M.; Caccavello, R. J.; Nelson, S.; Motter, R.; Wright, S.; Chian, D.; Santiago, P.; Soriano, F.; Ramos, C.; Powell, K.; Goldstein, J. M.; Babcock, M.; Yednock, T.; Bard, F.; Basi, G. S.; Sham, H.; Chilcote, T. J.; McConlogue, L.; Griswold-Prenner, I.; Anderson, J. P. *J Biol Chem* **2009**, *284*, 2598.

(34) Paleologou, K. E.; Oueslati, A.; Shakked, G.; Rospigliosi, C. C.; Kim, H. Y.; Lamberto, G. R.; Fernandez, C. O.; Schmid, A.; Chegini, F.; Gai, W. P.; Chiappe, D.; Moniatte, M.; Schneider, B. L.; Aebischer, P.; Eliezer, D.; Zweckstetter, M.; Masliah, E.; Lashuel, H. A. *J Neurosci* **2010**, *30*, 3184.

(44) Ahn, B. H.; Rhim, H.; Kim, S. Y.; Sung, Y. M.; Lee, M. Y.; Choi, J. Y.; Wolozin, B.; Chang, J. S.; Lee, Y. H.; Kwon, T. K.; Chung, K. C.; Yoon, S. H.; Hahn, S. J.; Kim, M. S.; Jo, Y. H.; Min, D. S. *The Journal of biological chemistry* **2002**, *277*, 12334.

(49) Anderson, J. P.; Walker, D. E.; Goldstein, J. M.; de Laat, R.; Banducci, K.; Caccavello, R. J.; Barbour, R.; Huang, J.; Kling, K.; Lee, M.; Diep, L.; Keim, P. S.; Shen, X.; Chataway, T.; Schlossmacher, M. G.; Seubert, P.; Schenk, D.; Sinha, S.; Gai, W. P.; Chilcote, T. J. *J Biol Chem* **2006**, *281*, 29739.